Stock info Spectrum Pharmaceuticals | Filter  Basic-Info

Spectrum Pharmaceuticals

The core activities of Spectrum Pharmaceuticals are in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The past year was a good year for Spectrum Pharmaceuticals investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Spectrum Pharmaceuticals, the stock lost around 21 percent. Over the period from December 2011 till December 2016 the stock lost on average 68 percent. Spectrum Pharmaceuticals's revenues between 2011 and 2015 were very volatile and moved between 267,71 million dollars and 162,56 million dollars. Spectrum Pharmaceuticals's net results between 2011 and 2015 were very fluctuating and moved between 48,52 million dollars and -50,79 million dollars.

Over the past 5 years the American company paid out dividends.

Healthy financed: not so much debt Spectrum Pharmaceuticals

At the end of 2015 the American company had a balance sheet of around 421,22 million dollars. At the end of 2015 the total debt positon equaled 208,36 million dollars. This is around 49,47 percent of the total balance sheet. As per the end of 2015 Spectrum Pharmaceuticals's price/earnings-ratio equaled -9. So investors paid for 1 stock -9 times the earnings per share of 2015. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 382,81 million dollars. At the end of 2015 around 64,88 million stocks were listed.

All Spectrum Pharmaceuticals's annual reports can be found here. More information about Spectrum Pharmaceuticals can be found it's website. .